Hematologic Malignancy
Monoclonal Immunoglobulin Deposition Disease
CI-CAN-00006049Explore in graph →
HematologicNon-malignant37 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006049Explore in graph →
Clinical trials
148 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06539169 | FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases | unknown | — | 1,000 | xCuresINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05635266 | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | unknown | — | 20,000 | Sanguine BiosciencesINDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT05066607 | Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy(IsAMYP) | unknown | Phase 2 | 46 | Intergroupe Francophone du MyelomeNETWORK | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06186167 | Amyloidosis Incidence in High-Risk Cardiac Device Patients | unknown | — | 100 | Midwest Heart & Vascular SpecialistsOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 108 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT05174338 | Cardiac Amyloidosis Registry Study(CARS) | unknown | — | 5,000 | Cedars-Sinai Medical CenterOTHER | 2 | Sep 6, 2023 | clinicaltrials |
| NCT05776940 | Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis | unknown | Phase 3 | 116 | Air Force Military Medical University, ChinaOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT03252600 | Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | unknown | Phase 2 | 53 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT05277493 | A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab | unknown | — | 500 | Peking Union Medical College HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04612582 | Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | unknown | Phase 4 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 3, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Nov 14, 2024source: clinicaltrials